DEBUG: Data/Datum
Datum[@Name='Schema Config DCR']Royal Bank of Canadahttps://www.rbcroyalbank.com/personal.htmlhttps://www.rbcroyalbank.com/personal.htmlInsights1200630enCA
Datum[@Name='Source DCR']2020-05-26New business models emergeWill genetics usher in a new era of healthcare? Is the entire health ecosystem ready for reinvention? Can digital healthcare in life sciences exceed patient expectations?Expanding Ecosystems3/assets/rbccm/images/gib/healthcare/article_3_thumbnail_sm.jpg/assets/rbccm/images/gib/healthcare/article_3_thumbnail.jpg<h3>Shifting Paradigms</h3>
<p>As the convergence of healthcare and technology has accelerated, new business models are rapidly emerging. </p>
<p>In the traditional biopharma model, the customer would be a physician, R&D tools would be chemical or biological, the end product a pill or vial, and the competitors pharma and biotech players.</p>
<p>The digital revolution in healthcare is shifting this long-established paradigm. Today, biopharma companies’ customer groups have grown to include patients of all ages, providers and payers—all equipped with smartphones and apps that generate a vast amount of digital information to empower their decision-making. R&D has added genetic information and digital capability to its toolset. The end product has broadened beyond the pill to include health outcomes enabled by digital devices and therapeutics. And the competitive set has seen the addition of technology players, including consumer-focused apps and online services, as well as digital health and digital therapeutics firms.</p>
<p class="photo-frame text-center"><img style="width: 100%;" src="/assets/rbccm/images/gib/healthcare/Healthcare-Article-3-Graph-1.png" alt="" /></p>
<h3>A Changing Ecosystem</h3>
<p>Indeed, digital and AI applications are radically changing key areas of the biopharma ecosystem and how patients manage their healthcare.</p>
<p>In pre-clinical research, technology is enabling everything from a deeper mining of literature, to predictive modeling and gene-function annotation. Digital apps are simulating molecular dynamics and pushing the limits of cellular imaging.</p>
<p>In clinical trials, digital transformation is helping to automate testing procedures, build global patient databases and collect real-world data.</p>
<p>In diagnostics, tech powers digital pathology, home-based body diagnosis, and computational analysis of tissue arrays. Just like your car leaves the factory with hundreds of sensors that can trigger the check engine light, humans will have wearable and/or implantable sensors to alert them when something is not functioning properly. Another burgeoning area is immune cell monitoring and digital analysis through just a finger prick.</p>
<p>At the point of patient care, digital applications are already delivering virtual consultations, remote monitoring, VR-based cognitive therapy and digital Rx. Demand for telehealth services and health-based social platforms is also increasing and especially vital in a world facing new challenges such as the COVID-19 pandemic.</p>
<p><img src="/assets/rbccm/images/gib/healthcare/healthcare-article-3-graph-2.png" alt="AI and Digital applications are changing key areas of the Healthcare Ecosystem" /></p>
<div id="similar-to-this" style="border-top: 2px #E6E6E7 dotted; border-bottom: 2px #E6E6E7 dotted; margin: 35px 0; padding: 25px;">
<h4 style="font-size: 18px; letter-spacing: 0.5px; border-bottom: 3px #FEDF01 solid; padding: 0 0 8px 0; margin-bottom: 15px;">Similar to this</h4>
</div>
<h3>Digital Transformation</h3>
<p>The digital revolution presents both threats and opportunities to incumbent biopharma companies. Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities from treatment to prevention.</p>
<div class="quotebox">
<p>“Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities.”</p>
<p class="attribution" style="color: #0070a3;">– Greg Wiederrecht, Ph.D.</p>
<div class="quote-share">
<p style="display: inline-block;"><span style="margin-right: 15px;">Share </span><a class="blue-circle-outline-sm" href="https://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New%20healthcare%20business%20models%20emerge&source=www.rbccm.com" target="_blank" rel="noopener" aria-label="Connect by LinkedIn"><em class="fa fa-linkedin" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="https://twitter.com/home?status=New%20business%20models%20emerge%20https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge" target="_blank" rel="noopener" aria-label="Connect by X"><em class="fa fa-twitter" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="mailto:?subject=New%20business%20models%20emerge&body=I%20found%20this%20insights%20piece%20from%20RBC%20Capital%20Markets%20informative%20and%20thought%20it%20might%20be%20of%20interest%20to%20you%3A%0D%0Dhttps%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New business models emerge" aria-label="Connect by Email"><em class="fa fa-envelope" style="color: #0051a5; margin-left: 3px;"> </em></a></p>
</div>
</div>
<p> </p>
<p>The increased digitization of human experiences gives access to a wealth of information and knowledge that could help intervene before disease has a chance to strike. A prime example of this is collating data from an Apple Watch to screen for irregular heart rhythms and detect undiagnosed atrial fibrillation. At the other end of the spectrum, digital transformation allows a completely new class of therapies such as digital therapeutics to support specific disorders.</p>
<p>McKinsey and Company’s international survey shows that more than 75% of patients expect to use digital healthcare services in the future.<sup>1</sup> Patients are seeking technology that delivers a level of care they can rely on and trust. Ultimately, the aim of the digital revolution is to develop healthier societies and lower the cost of care.</p>
<p style="word-wrap: break-word;"><sup>1 Source: McKinsey and Company, Healthcare’s Digital Future, July 2014. https://www.mckinsey.com/~/media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/Healthcares%20digital%20future/Healthcares%20digital%20future.ashx</sup></p><ul>
<li>Customer groups, R&D and competitors are all rapidly expanding</li>
<li>Tech is reinventing every facet of the biopharma ecosystem</li>
<li>Innovations in patient care is driving adoption of digital services</li>
</ul>text2 min1 minHealthcare Models, Digital Healthcare, Digital Healthcare Apps, Digital Health Diagnostics, Expanding R&D, Healthcare & Tech Convergence, Healthcare Services, Clinical Trials, Remote Patient Monitoring, Digital Therapeutics, Biopharma ecosystem, Cost of CareN/templatedata/rbccm/episode/data/healthcare/amazon_cvs_and_google_healthcare_reimagined/templatedata/rbccm/episode/data/healthcare/big_tech_vs_big_pharma/templatedata/rbccm/episode/data/healthcare/the_healthcare_data_explosionGreg Wiederrecht, Ph.D./assets/rbccm/images/gib/healthcare/greg-wiederrecht.jpgManaging Director, Healthcare Investment Bankinggreg.wiederrecht@rbccm.comhttps://www.linkedin.com/in/gregwiederrecht/Sasson Darwish/assets/rbccm/images/gib/healthcare/sasson-darwish.jpgManaging Director, AI, Analytics and IoT & Israel Country Coverage, Global Technology Investment Bankingsasson.darwish@rbccm.com https://www.linkedin.com/in/sassdarwish/Andrew Callaway/assets/rbccm/images/gib/healthcare/andrew-callaway.jpgManaging Director, Global Head of Healthcare Investment Bankingandrew.callaway@rbccm.comhttps://www.linkedin.com/in/andrew-cal-callaway
DEBUG: DCR
DCRRoyal Bank of Canadahttps://www.rbcroyalbank.com/personal.htmlhttps://www.rbcroyalbank.com/personal.htmlInsights1200630enCA
DCR2020-05-26New business models emergeWill genetics usher in a new era of healthcare? Is the entire health ecosystem ready for reinvention? Can digital healthcare in life sciences exceed patient expectations?Expanding Ecosystems3/assets/rbccm/images/gib/healthcare/article_3_thumbnail_sm.jpg/assets/rbccm/images/gib/healthcare/article_3_thumbnail.jpg<h3>Shifting Paradigms</h3>
<p>As the convergence of healthcare and technology has accelerated, new business models are rapidly emerging. </p>
<p>In the traditional biopharma model, the customer would be a physician, R&D tools would be chemical or biological, the end product a pill or vial, and the competitors pharma and biotech players.</p>
<p>The digital revolution in healthcare is shifting this long-established paradigm. Today, biopharma companies’ customer groups have grown to include patients of all ages, providers and payers—all equipped with smartphones and apps that generate a vast amount of digital information to empower their decision-making. R&D has added genetic information and digital capability to its toolset. The end product has broadened beyond the pill to include health outcomes enabled by digital devices and therapeutics. And the competitive set has seen the addition of technology players, including consumer-focused apps and online services, as well as digital health and digital therapeutics firms.</p>
<p class="photo-frame text-center"><img style="width: 100%;" src="/assets/rbccm/images/gib/healthcare/Healthcare-Article-3-Graph-1.png" alt="" /></p>
<h3>A Changing Ecosystem</h3>
<p>Indeed, digital and AI applications are radically changing key areas of the biopharma ecosystem and how patients manage their healthcare.</p>
<p>In pre-clinical research, technology is enabling everything from a deeper mining of literature, to predictive modeling and gene-function annotation. Digital apps are simulating molecular dynamics and pushing the limits of cellular imaging.</p>
<p>In clinical trials, digital transformation is helping to automate testing procedures, build global patient databases and collect real-world data.</p>
<p>In diagnostics, tech powers digital pathology, home-based body diagnosis, and computational analysis of tissue arrays. Just like your car leaves the factory with hundreds of sensors that can trigger the check engine light, humans will have wearable and/or implantable sensors to alert them when something is not functioning properly. Another burgeoning area is immune cell monitoring and digital analysis through just a finger prick.</p>
<p>At the point of patient care, digital applications are already delivering virtual consultations, remote monitoring, VR-based cognitive therapy and digital Rx. Demand for telehealth services and health-based social platforms is also increasing and especially vital in a world facing new challenges such as the COVID-19 pandemic.</p>
<p><img src="/assets/rbccm/images/gib/healthcare/healthcare-article-3-graph-2.png" alt="AI and Digital applications are changing key areas of the Healthcare Ecosystem" /></p>
<div id="similar-to-this" style="border-top: 2px #E6E6E7 dotted; border-bottom: 2px #E6E6E7 dotted; margin: 35px 0; padding: 25px;">
<h4 style="font-size: 18px; letter-spacing: 0.5px; border-bottom: 3px #FEDF01 solid; padding: 0 0 8px 0; margin-bottom: 15px;">Similar to this</h4>
</div>
<h3>Digital Transformation</h3>
<p>The digital revolution presents both threats and opportunities to incumbent biopharma companies. Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities from treatment to prevention.</p>
<div class="quotebox">
<p>“Tech is powering efficiencies in all stages of the current ecosystem and is also enabling healthcare providers to expand their capabilities.”</p>
<p class="attribution" style="color: #0070a3;">– Greg Wiederrecht, Ph.D.</p>
<div class="quote-share">
<p style="display: inline-block;"><span style="margin-right: 15px;">Share </span><a class="blue-circle-outline-sm" href="https://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New%20healthcare%20business%20models%20emerge&source=www.rbccm.com" target="_blank" rel="noopener" aria-label="Connect by LinkedIn"><em class="fa fa-linkedin" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="https://twitter.com/home?status=New%20business%20models%20emerge%20https%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge" target="_blank" rel="noopener" aria-label="Connect by X"><em class="fa fa-twitter" style="color: #0051a5; margin-left: 3px;"> </em></a> <a class="blue-circle-outline-sm" href="mailto:?subject=New%20business%20models%20emerge&body=I%20found%20this%20insights%20piece%20from%20RBC%20Capital%20Markets%20informative%20and%20thought%20it%20might%20be%20of%20interest%20to%20you%3A%0D%0Dhttps%3A//www.rbccm.com/en/gib/healthcare/episode/new_healthcare_business_models_emerge&title=New business models emerge" aria-label="Connect by Email"><em class="fa fa-envelope" style="color: #0051a5; margin-left: 3px;"> </em></a></p>
</div>
</div>
<p> </p>
<p>The increased digitization of human experiences gives access to a wealth of information and knowledge that could help intervene before disease has a chance to strike. A prime example of this is collating data from an Apple Watch to screen for irregular heart rhythms and detect undiagnosed atrial fibrillation. At the other end of the spectrum, digital transformation allows a completely new class of therapies such as digital therapeutics to support specific disorders.</p>
<p>McKinsey and Company’s international survey shows that more than 75% of patients expect to use digital healthcare services in the future.<sup>1</sup> Patients are seeking technology that delivers a level of care they can rely on and trust. Ultimately, the aim of the digital revolution is to develop healthier societies and lower the cost of care.</p>
<p style="word-wrap: break-word;"><sup>1 Source: McKinsey and Company, Healthcare’s Digital Future, July 2014. https://www.mckinsey.com/~/media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/Healthcares%20digital%20future/Healthcares%20digital%20future.ashx</sup></p><ul>
<li>Customer groups, R&D and competitors are all rapidly expanding</li>
<li>Tech is reinventing every facet of the biopharma ecosystem</li>
<li>Innovations in patient care is driving adoption of digital services</li>
</ul>text2 min1 minHealthcare Models, Digital Healthcare, Digital Healthcare Apps, Digital Health Diagnostics, Expanding R&D, Healthcare & Tech Convergence, Healthcare Services, Clinical Trials, Remote Patient Monitoring, Digital Therapeutics, Biopharma ecosystem, Cost of CareN/templatedata/rbccm/episode/data/healthcare/amazon_cvs_and_google_healthcare_reimagined/templatedata/rbccm/episode/data/healthcare/big_tech_vs_big_pharma/templatedata/rbccm/episode/data/healthcare/the_healthcare_data_explosionGreg Wiederrecht, Ph.D./assets/rbccm/images/gib/healthcare/greg-wiederrecht.jpgManaging Director, Healthcare Investment Bankinggreg.wiederrecht@rbccm.comhttps://www.linkedin.com/in/gregwiederrecht/Sasson Darwish/assets/rbccm/images/gib/healthcare/sasson-darwish.jpgManaging Director, AI, Analytics and IoT & Israel Country Coverage, Global Technology Investment Bankingsasson.darwish@rbccm.com https://www.linkedin.com/in/sassdarwish/Andrew Callaway/assets/rbccm/images/gib/healthcare/andrew-callaway.jpgManaging Director, Global Head of Healthcare Investment Bankingandrew.callaway@rbccm.comhttps://www.linkedin.com/in/andrew-cal-callaway
DEBUG: Data/Result
12024-01-23Back to the Future for the 2024 Deal Landscape?Familiar fixtures are set to return to private equity M&A. Conventional financing is starting to look more attractive again.Strategic Alternativesglobalmarkets/assets/rbccm/images/insights/2024/consumer-pe-4-th.jpghttps://player.captivate.fm/episode/b3ac45a3-559c-4446-b3bb-44d73ced54ca/assets/rbccm/images/insights/2024/consumer-pe-4-banner.jpghttps://www.rbccm.com/en/insights/story.page?dcr=templatedata/article/story/data/2024/02/2024-will-have-ma-volumes-much-morestrategic<p>
<script>
$(".lead").html("Familiar fixtures are set to return to private equity M&A. Conventional financing is starting to look more attractive again; traditional sales are poised to re-enter to the mix. Meanwhile, cyclical industrials are among the sectors well placed to lead the way in deal activity.");
</script>
</p>
<div style="width: 100%; height: 200px; margin-bottom: 20px; border-radius: 6px; overflow: hidden;"><iframe style="width: 100%; height: 200px;" title="Back to the Future for the 2024 Deal Landscape?" src="https://player.captivate.fm/episode/b3ac45a3-559c-4446-b3bb-44d73ced54ca" frameborder="no" scrolling="no" seamless=""></iframe></div>
<p><a title="ECM’s 2024 Rebound: Rebalancing the Equation - Transcript" href="/en/insights/transcripts/2024-will-have-ma-volumes-much-more.page">View audio transcript</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><a style="margin: 0 20px 0 0; display: inline-block;" title="Listen on Apple Podcasts" href="https://podcasts.apple.com/us/podcast/strategic-alternatives/id1666646938" target="_blank" rel="noopener"><img style="margin-bottom: 30px; height: 40px;" src="/assets/rbccm/images/insights/US_UK_Apple_Podcasts_Listen_Badge_RGB.svg" alt="Listen on Apple Podcasts" height="40" /></a> <a style="margin: 0 20px 0 0; display: inline-block;" title="Listen on Spotify" href="https://open.spotify.com/show/0pEPiiVvPTUgyMxe7F2dwN" target="_blank" rel="noopener"><img style="margin-bottom: 30px; border: 1px rgba(255, 255, 255, 0.5) solid; border-radius: 5px; height: 40px;" src="/assets/rbccm/images/insights/spotify-podcast-badge-blk-grn-165x40.svg" alt="Listen on Spotify" height="40" /></a> <a style="margin: 0 20px 0 0; display: inline-block;" title="Listen on Google Play Music" href="https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5jYXB0aXZhdGUuZm0vbWEtaW5mbGVjdGlvbi1wb2ludHM" target="_blank" rel="noopener"><img style="margin-bottom: 30px; height: 40px;" src="/assets/rbccm/images/insights/google-podcasts-badge.png?v2" alt="Listen on Google Play Music" height="40" /></a></div>
<hr />
<h2>Are sellers waiting for a credible IPO market to provide a realistic alternative to a sales process?</h2>
<p><strong>Hank Johnson</strong>: A lot of our private equity sponsors have a bias towards a sale and a complete exit. That said, the path to go public is, for very large companies, just more actionable, because the buyer universe is smaller and it’s harder. But the leverage profile is very different in public. While some of those businesses have grown, there is a deleveraging that’s required to go public.</p>
<p><strong>Vito Sperduto</strong>: You’re certainly going to consider alternatives – a partial monetization, a partial sale, a continuation fund. But when the ability to execute a traditional LBO is more realizable in the market, you’re going to see people pivot to that.</p>
<blockquote>
<p>“When the ability to execute a traditional LBO is more realizable, you’re going to see people pivot to that.”</p>
<p class="attribution">Vito Sperduto, Global Head of M&A</p>
</blockquote>
<h2>Private credit has filled the gap for private equity in a tough financing environment – will that slow down as the market changes?</h2>
<p><strong>John Cokinos</strong>: We saw private credit take a lot of share over the last 18 months. In a lower rate environment, I think you will see that some of those deals that were done at the SOFR 600 to 700 level, we will be able to refinance those at compelling rates. That will be a better cost of capital achieved for the owners, improving their IRRs.</p>
<p>Private credit is here to stay. It is going to be part of the ecosystem of leveraged finance. It’s good for middle market financings, and it is able to take advantage of market dislocations, when rates get higher or when banks are sidelined.</p>
<blockquote>
<p>‘Private credit is here to stay – it’s going to be part of the ecosystem of leveraged finance’</p>
<p class="attribution">John Cokinos, Global Head of Leveraged Finance and Capital Markets</p>
</blockquote>
<h2>What sectors will be leading the way for deal activity in 2024?</h2>
<p><strong>Sperduto:</strong> We have seen robust activity across the board in our pipeline. Certainly some of the energy M&A that’s been happening on the corporate side has been a big boost to the business. We are seeing a lot of healthcare and technology M&A, as we do every year.</p>
<p><strong>Johnson:</strong> There are housing-related opportunities as mortgage rates come down. Infrastructure funds are broadening their scope. Business services has always been a very active area within private equity, and we expect that to continue; we’ve seen activity in HVAC and plumbing, a continued rise in outsourcing opportunities, and a broader scope of asset managers, financial and insurance brokerage. Within every industry group, there are sectors we believe are well positioned for this coming year.</p>
<p><strong>Cokinos:</strong> We expect to see a healthy amount in the industrial space – aerospace, defense, transportation, building products, and capital goods. I think you will see more demand for consumer situations as well. Healthcare is going to be a little challenging because we are in an election year and people get very worried about government change.</p>
<blockquote>
<p>“Within every industry group, there are sectors we believe are well positioned for this coming year.”</p>
<p class="attribution">Hank Johnson, Co-head of U.S. M&A</p>
</blockquote>
<h2>What are your general expectations for the market in 2024?</h2>
<p><strong>Sperduto</strong>: In the second half of the year, the US presidential election and the large number of elections going on globally will give some pause. But companies and clients, with the pent-up demand and also with their experience historically, are prepared to operate through that.</p>
<blockquote>
<p>“Election year will give some pause – but companies are prepared to operate through that.”</p>
<p class="attribution">Vito Sperduto, Global Head of M&A</p>
</blockquote>
<p><strong>Johnson:</strong> I’m looking forward to an increase in transaction volume with our private equity clients. I expect ’24 will have M&A volumes much more in line with historical levels, with the potential to exceed those. That is very encouraging.</p>
<p><strong>Cokinos:</strong> The markets haven’t felt this good in 18 months. It may be back-loaded this year, but I do think we will see a pretty vibrant market.</p>
<p> </p><ul>
<li>A reemerging IPO market may provide alternative exit paths in 2024, but most private equity players will prefer to sell where possible.</li>
<li>Private credit will remain part of the leverage mix, though its recent importance will recede as companies seek to refinance.</li>
<li>Energy and healthcare tech lead deal activity, with further strong opportunities in infrastructure, business services, and industrials.</li>
<li>US and global elections are unlikely to cause significant disruption to deal activity.</li>
</ul>audio2 min16 minStrategic alternatives podcast, private equity insights, rbc podcast, vito sperduto rbc, M&A insights, M&A trends, leveraged finance market, interest rates, M&A activityenglobalma-inflection-points1/templatedata/rbccm/authors/data/vito-sperdutovito-sperdutoVito SperdutoGlobal Head, Mergers & AcquisitionsN/assets/rbccm/images/authors/vito-sperduto.jpghttps://www.linkedin.com/in/vito-sperduto<p><strong>Vito Sperduto</strong> is the Global head of Mergers and Acquisitions at RBC Capital Markets.</p>
<p>He is responsible for the bank’s overall M&A effort across all industry sectors. Historically, he has extensive sector experience with origination and execution of transactions in industrials (with a focus on aerospace, defense and government services), communications, media and entertainment, technology, and business services.</p>
<p>Vito has over 27 years of investment banking experience, during which he has advised on over 150 transactions with a combined value exceeding $100 billion.</p>
<p>Prior to RBC, Vito was most recently Managing Director and Head of Software M&A coverage for CIBC World Markets in New York, where he worked across the defense, consumer, business services and technology sectors.</p>
<p>He has previously worked for SoundView Technology Group, Smith Barney and Kidder, Peabody.</p>
<p>Vito earned his B.A. from Harvard University in Computer Science / Engineering Sciences.</p>/templatedata/rbccm/authors/data/larry-grafsteinlarry-grafsteinLarry Grafstein Deputy Chairman, Global Investment BankingN/assets/rbccm/images/authors/Larry%20Grafstein.jpghttps://www.linkedin.com/in/larry-grafstein-4597a219b/<p><strong>Larry Grafstein</strong> has been Deputy Chairman of the Global Investment Banking at RBC Capital Markets since September of 2018. In his 30 years on Wall Street, he has advised clients on nearly $1 trillion of completed transactions. His experience spans all industries and geographies and includes some of the largest and most complex M&A, restructuring, equity and privatization deals. </p>
<p>His clients over the years have included AerCap, AT&T, BAT, Charter Communications, Creative Artists Agency, Fiat Chrysler Automobiles, Hutchison Whampoa, Intel, Jabil, Juniper, Leucadia, Level 3, Microsoft, Mosaic, Sprint, Time Warner, TPG, Visteon and Vodafone. Recently he advised CSX on its response to activist investor Mantle Ridge, IBM on its acquisition of Truven, and Molson Coors on its acquisition of its Miller Coors JV. He advised on the restructurings of WorldCom and Nortel, two of the largest done to date. </p>
<p>He has worked on behalf of the Governments of Canada and Ontario regarding their investments in Chrysler and General Motors after the financial crisis and advised on the landmark privatizations of Telefonos de Mexico and Telstra of Australia. He recently represented Statewide Mobility Partners, a consortium of investment funds, on the divestiture of Indiana Toll Roads, one of the largest infrastructure sales in US history. In 2014 he helped settle the strike and consumer boycott at Market Basket Supermarkets in New England through the sale by certain members of the Demoulas family of their ownership stake and resolution of their 20-year control dispute.</p>
<p>Mr. Grafstein is a graduate of Harvard University (B.A.), Oxford University (M.Phil, Balliol College, Rhodes Scholar), and the University of Toronto (J.D.). He is co-chair of his Harvard class and has served on the board of a number of public companies and philanthropic institutions, including the US board of Upper Canada College and the board of trustees of Horace Mann School in New York.</p>/templatedata/rbccm/authors/data/john-cokinosjohn-cokinosJohn CokinosGlobal Head, Leveraged Finance & Capital MarketsN/assets/rbccm/images/authors/john-cokinos.jpghttps://www.linkedin.com/in/john-cokinos-90008a49<p><strong>John Cokinos</strong> is the Co-Head of US Leveraged Finance and Capital Markets at RBC. He joined the US leveraged finance and capital markets team at RBC Capital Markets in March 2014. He and Mr. Charles Smith oversee all origination and distribution activities under the leveraged finance business. Mr. Cokinos focuses on acquisition finance and private equity transactions with specific industry expertise in Technology, Healthcare, Financial Services and Industrials.</p>
<p>Prior to joining RBC, he spent 7 years at Bank America Merrill Lynch, where his last role was head of leverage finance capital markets. Before joining BAML, Mr. Cokinos worked at Lehman Brothers from 1998 until 2007. He is a graduate of Cornell University with a BS in Business Administration, class of 1995. He is a board member of the Fiver Children’s Foundatoin, a non-profit organization that helps New York City youth. Mr. Cokinos resides in Manhattan with his wife and three children. </p>/templatedata/rbccm/authors/data/hank-johnsonhank-johnsonHenry JohnsonCo-Head, US Mergers & AcquisitionsN/assets/rbccm/images/authors/hank-johnson.jpghttps://www.linkedin.com/in/henry-johnson-1345106a/<p><strong>Henry Johnson</strong> is a Managing Director and Co-Head of U.S. Mergers and Acquisitions at RBC Capital Markets. He joined RBC in 2013 and has over 20 years of investment banking experience. Prior to joining RBC, Henry was a Managing Director at Barclays, and previously worked at Lehman Brothers.</p>
<p>Henry received his A.B. in Economics from Duke University and an MBA from Duke’s Fuqua School of Business.</p>Vito Sperduto, Larry Grafstein, John Cokinos and Henry JohnsonVito Sperduto, Larry Grafstein, John Cokinos and Henry JohnsonN/templatedata/article/story/data/2024/01/ecm-2024-rebound-rebalancing-the-equation/templatedata/article/story/data/2024/01/ma-2024-comeback-a-buyer-market/templatedata/article/story/data/2023/12/2024-global-macroeconomic-outlook/templatedata/article/story/data/2023/12/2024-global-macroeconomic-outlookRBC’s M&A experts discuss which sectors may be a bright lift for private equity M&A activity in 2024 in the Strategic Alternatives podcast.
Strategic alternatives podcast, private equity insights, rbc podcast, vito sperduto rbc, M&A insights, M&A trends, leveraged finance market, interest rates, M&A activity